ANXA5 and neoplasm: Recent research points out that the application of fusion protein combines ANXA5, an ovarian tumor- and tumor vasculature-targeting protein, with mutated cystathionine gamma-lyase (mCTH), an enzyme that converts selenomethionine (SeMet) into toxic methylselenol, which generates reactive oxygen species, leading to eventual tumor cell death [65].